Health Affairs' Rob Lott interviews Anna Zink of Tufts University about on her recent paper examining studies of an FDA‑approved cardiac diagnostic AI tool, fractional flow reserve derived from computed tomography. They discuss how the tool shifts testing patterns, raises some costs, reduces invasive procedures, and may improve outcomes—along with what it all means for Medicare reimbursement and the future of AI regulation.

Order the March 2026 issue of Health Affairs.

Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast